Annexon, Inc. (NASDAQ:ANNX) CEO Douglas Love sold 3,750 shares of the firm’s stock in a transaction on Monday, June 7th. The shares were sold at an average price of $22.31, for a total value of $83,662.50. Following the sale, the chief executive officer now directly owns 3,750 shares of the company’s stock, valued at $83,662.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Douglas Love also recently made the following trade(s):
- On Thursday, April 1st, Douglas Love sold 500 shares of Annexon stock. The shares were sold at an average price of $28.08, for a total transaction of $14,040.00.
- On Monday, March 29th, Douglas Love sold 3,750 shares of Annexon stock. The stock was sold at an average price of $25.42, for a total transaction of $95,325.00.
Annexon stock opened at $22.84 on Friday. Annexon, Inc. has a 1-year low of $15.33 and a 1-year high of $38.01. The company has a market cap of $873.84 million and a price-to-earnings ratio of -0.74. The business’s 50 day moving average price is $21.76.
A number of institutional investors have recently bought and sold shares of the stock. Satter Management CO. L.P. purchased a new position in shares of Annexon during the fourth quarter worth about $48,933,000. Federated Hermes Inc. grew its stake in Annexon by 39.2% in the 1st quarter. Federated Hermes Inc. now owns 2,000,700 shares of the company’s stock worth $55,699,000 after buying an additional 563,700 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Annexon by 16.5% in the 1st quarter. BlackRock Inc. now owns 2,898,321 shares of the company’s stock worth $80,688,000 after buying an additional 410,988 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Annexon by 27.4% during the 1st quarter. Alliancebernstein L.P. now owns 1,447,155 shares of the company’s stock worth $40,289,000 after acquiring an additional 311,677 shares during the last quarter. Finally, Holocene Advisors LP bought a new position in Annexon in the first quarter valued at $7,925,000. Institutional investors and hedge funds own 97.83% of the company’s stock.
Separately, Zacks Investment Research downgraded Annexon from a “hold” rating to a “sell” rating in a research note on Monday, March 29th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Annexon has an average rating of “Buy” and an average price target of $34.33.
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.
Read More: What are catch-up contributions?
Receive News & Ratings for Annexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annexon and related companies with MarketBeat.com's FREE daily email newsletter.